Striking idea: tissues may “recover,” but cells remember.
AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← KRAS / RAS targeting: from platform to Phase 3
#EOCRC
2 people · 2 posts
Other cases in this chapter
- daraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40
- daraxonrasib ± GnPmono ORR 47%; +GnP ORR 55%, DCR 90%
- zoldonrasibORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73%
- VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
- elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
- RM-055Active in daraxonrasib-resistant and RAS-amplification models
Floor